Promoted Content
Promoted Content

Find Gastroenterology Drugs in Phase II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GB004

            Therapeutic Area: Gastroenterology Product Name: GB004

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2020

            Details:

            Gossamer Bio will present data relevant to GB004 at United European Gastroenterology Virtual Week 2020, which takes place from October 11th through 13th.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lovastatin Lactone

            Therapeutic Area: Gastroenterology Product Name: SYN-010

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 02, 2020

            Details:

            CSMC has decided discontinue the trial and will conduct a comprehensive review of the final data set, based on the review of the interim analysis. SYN-010 was well-tolerated but it is unlikely to meet its primary objective by the time enrollment is completed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRV-015

            Therapeutic Area: Gastroenterology Product Name: AMG 714

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            PRV-015 (anti-interleukin-15) is the first investigational product to show both a reduction in gluten-induced symptoms and in markers of intestinal inflammation in a placebo-controlled trial in celiac subjects .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AMT-101

            Therapeutic Area: Gastroenterology Product Name: AMT-101

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            First patient has been dosed in a randomized, placebo-controlled, double-blind, multicenter Phase 2a study evaluating the efficacy and safety of oral AMT-101 in patients with moderate to severely active ulcerative colitis (UC).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Macrogol API,Electrolytes

            Therapeutic Area: Gastroenterology Product Name: Colonoscopy prep

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 21, 2020

            Details:

            The investigational prep is designed to be good-tasting and easy-to-consume, with no fasting and lower fluid requirements than standard preps.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORP-101

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 02, 2020

            Details:

            OrphoMed paused screening of new patients on March 27, 2020, in response to the COVID-19 pandemic. Now the company announces resumption of patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AG013

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2020

            Details:

            Phase 2 clinical trial of AG013 in head and neck cancer did not demonstrate statistical significance on the primary endpoint of severe oral mucositis duration when compared to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORP-101

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2020

            Details:

            OrphoMed has paused new patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D) in response to the COVID-19 pandemic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORP-101

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 19, 2020

            Details:

            ORP-101 currently in phase 2 study for treatment of irritable bowel syndrome with diarrhea.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Latiglutenase

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 13, 2020

            Details:

            The trial will test the safety and efficacy of the company’s lead therapeutic candidate, Latiglutenase (IMGX003).

            PharmaCompass